Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus XELOX as neoadjuvant therapy for locally advanced gastric cancer
ChiCTR1800018546Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Sep 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, oxaliplatin and capecitabine in gastric cancer (GC), sponsored by The First Hospital of Lanzhou University. Primary endpoints: pathologic complete response and objective response rate. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
Rivoceraniboxaliplatincapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1800018546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018546.